Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines

Guan, Xiao-Qing; Yang, Yang; Du, Lanying

doi:10.1080/14760584.2023.2211153

Cited by 14 publications

(5 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydrogels serve as formidable guardians, shielding vaccines from degradation and preserving their stability throughout the storage and transportation processes [8]. Within the hydrogel matrix, vaccines are safeguarded against temperature fluctuations, exposure to light, and enzymatic degradation, assuring their potency and therapeutic efficacy [153,159]. The hydrogel formulation bestows the unique ability to orchestrate a controlled and sustained release of the vaccine antigens, closely mirroring the natural kinetics of immune response [160].…”

Section: Vaccine Delivery Hydrogelsmentioning

confidence: 99%

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Hoc Thang,

Van Phuc,

Nhi

et al. 2024

Express Polym. Lett.

View full text Add to dashboard Cite

The COVID-19 pandemic has presented an array of challenges and given rise to a spectrum of diseases and health issues [1]. Foremost among the challenges of the pandemic is the swift transmission of the SARS-CoV-2 virus [2]. Strategies to curb transmission encompass extensive vaccination campaigns [3], the implementation of public health measures like mask-wearing [4] and social distancing [4], and the promotion of hygiene practices such as frequent handwashing [5]. The SARS-CoV-2 virus, which causes COVID-19, primarily targets the respiratory system [6]. However, it can also precipitate various complications and impact other organs and bodily systems [7]. COVID-19, an abbreviation for Coronavirus Disease 2019, is the ailment brought about by the SARS-CoV-2 virus [8]. It manifests as a broad spectrum of symptoms, spanning from mild to severe respiratory ailments [9]. Common symptoms include fever, cough, shortness of breath, fatigue, loss of taste or smell, and body aches [10]. In severe instances, it can progress to pneumonia and acute

show abstract

Section: Vaccine Delivery Hydrogelsmentioning

confidence: 99%

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Hoc Thang,

Van Phuc,

Nhi

et al. 2024

Express Polym. Lett.

View full text Add to dashboard Cite

show abstract

“…Critically, the S protein induces specific neutralizing antibodies (nAbs) that can block the RBD-human angiotensin-converting enzyme 2 (hACE2) interaction on host cells to prevent infection. Although all structural proteins of SARS-CoV-2 can induce nAbs, the S protein is highly immunogenic, and the RBD of the S protein is the most immunodominant target for inducing nAbs ( Guan et al., 2023 ). Therefore, the S protein and its RBD constitute two major antigen targets for the development of SARS-CoV-2 vaccines.…”

Section: Structure and Functions Of Sars-cov-2 S Protein And Rbdmentioning

confidence: 99%

Advances in virus-like particle-based SARS-CoV-2 vaccines

Hao,

Yuan,

Yao

2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has incurred devastating human and economic losses. Vaccination remains the most effective approach for controlling the COVID-19 pandemic. Nonetheless, the sustained evolution of SARS-CoV-2 variants has provoked concerns among the scientific community regarding the development of next-generation COVID-19 vaccines. Among these, given their safety, immunogenicity, and flexibility to display varied and native epitopes, virus-like particle (VLP)-based vaccines represent one of the most promising next-generation vaccines. In this review, we summarize the advantages and characteristics of VLP platforms, strategies for antigen display, and current clinical trial progress of SARS-CoV-2 vaccines based on VLP platforms. Importantly, the experience and lessons learned from the development of SARS-CoV-2 VLP vaccines provide insights into the development of strategies based on VLP vaccines to prevent future coronavirus pandemics and other epidemics.

show abstract

“…The detection of antibodies has proven advantageous over qPCR-based diagnosis due to the method's reduced reliance In addition to their role in diagnosis, antibodies are pivotal for the development of vaccines against SARS-CoV-2. Most COVID-19 vaccines are based on generating nAbs against viral antigens, specifically targeting the receptor-binding domain (RBD) of the spike (S) protein [20]. Multiple COVID-19 vaccines have now been developed, including mRNA vaccines produced by Moderna and Pfizer-BioNTech, as well as several adenovirus vector-based vaccines such as Sputnik-V and Oxford-AstraZeneca [21,22].…”

Section: Introductionmentioning

confidence: 99%

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Kumar,

Tripathi,

Kumar

et al. 2024

Vaccines

View full text Add to dashboard Cite

Understanding the antibody response to SARS-CoV-2, the virus responsible for COVID-19, is crucial to comprehending disease progression and the significance of vaccine and therapeutic development. The emergence of highly contagious variants poses a significant challenge to humoral immunity, underscoring the necessity of grasping the intricacies of specific antibodies. This review emphasizes the pivotal role of antibodies in shaping immune responses and their implications for diagnosing, preventing, and treating SARS-CoV-2 infection. It delves into the kinetics and characteristics of the antibody response to SARS-CoV-2 and explores current antibody-based diagnostics, discussing their strengths, clinical utility, and limitations. Furthermore, we underscore the therapeutic potential of SARS-CoV-2-specific antibodies, discussing various antibody-based therapies such as monoclonal antibodies, polyclonal antibodies, anti-cytokines, convalescent plasma, and hyperimmunoglobulin-based therapies. Moreover, we offer insights into antibody responses to SARS-CoV-2 vaccines, emphasizing the significance of neutralizing antibodies in order to confer immunity to SARS-CoV-2, along with emerging variants of concern (VOCs) and circulating Omicron subvariants. We also highlight challenges in the field, such as the risks of antibody-dependent enhancement (ADE) for SARS-CoV-2 antibodies, and shed light on the challenges associated with the original antigenic sin (OAS) effect and long COVID. Overall, this review intends to provide valuable insights, which are crucial to advancing sensitive diagnostic tools, identifying efficient antibody-based therapeutics, and developing effective vaccines to combat the evolving threat of SARS-CoV-2 variants on a global scale.

show abstract

Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines

Cited by 14 publications

References 145 publications

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus

Advances in virus-like particle-based SARS-CoV-2 vaccines

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Contact Info

Product

Resources

About